Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALPANASDAQ:BIVINASDAQ:CTXRNASDAQ:JYNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPAAlpha Healthcare Acquisition Corp. III$3.14$8.73▼$11.83$8.92M0.03128,666 shs85,427 shsBIVIBioVie$1.03-5.5%$1.02$0.62▼$7.50$19.13M0.771.85 million shs192,661 shsCTXRCitius Pharmaceuticals$1.08+18.3%$0.84$0.65▼$26.25$11.48M0.87658,302 shs2.90 million shsJYNTJoint$11.52+4.5%$10.53$9.58▼$15.32$176.29M1.4854,059 shs105,611 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPAAlpha Healthcare Acquisition Corp. III0.00%0.00%0.00%0.00%-72.17%BIVIBioVie-5.50%-9.65%+3.00%-8.04%+129.50%CTXRCitius Pharmaceuticals+18.34%+23.49%+58.59%-28.95%-92.92%JYNTJoint+4.54%+0.26%+15.08%-9.51%-17.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPAAlpha Healthcare Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/ABIVIBioVie2.2172 of 5 stars3.83.00.00.00.00.00.6CTXRCitius Pharmaceuticals1.8568 of 5 stars3.42.00.00.00.60.81.3JYNTJoint3.1453 of 5 stars3.53.00.00.00.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPAAlpha Healthcare Acquisition Corp. III 0.00N/AN/AN/ABIVIBioVie 3.50Strong Buy$3.00191.26% UpsideCTXRCitius Pharmaceuticals 2.80Moderate Buy$54.504,946.30% UpsideJYNTJoint 3.00Buy$15.5034.55% UpsideCurrent Analyst Ratings BreakdownLatest JYNT, ALPA, CTXR, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/9/2025JYNTJointLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPAAlpha Healthcare Acquisition Corp. IIIN/AN/AN/A923.23($0.31) per shareN/ABIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AJYNTJoint$51.90M3.40$0.65 per share17.63$1.20 per share9.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPAAlpha Healthcare Acquisition Corp. III$200KN/A0.00N/AN/AN/A-28.55%0.84%N/ABIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.000.86N/AN/A-58.63%-37.67%8/11/2025 (Estimated)JYNTJoint-$8.53M-$0.58N/A21.74N/A-9.86%1.60%0.41%8/6/2025 (Estimated)Latest JYNT, ALPA, CTXR, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/A5/8/2025Q1 2025JYNTJoint-$0.02-$0.03-$0.01$0.06$13.02 million$13.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPAAlpha Healthcare Acquisition Corp. IIIN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AJYNTJointN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPAAlpha Healthcare Acquisition Corp. IIIN/A0.050.05BIVIBioVieN/A9.319.31CTXRCitius PharmaceuticalsN/A0.370.06JYNTJointN/A1.591.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPAAlpha Healthcare Acquisition Corp. III67.49%BIVIBioVie4.59%CTXRCitius Pharmaceuticals16.88%JYNTJoint76.88%Insider OwnershipCompanyInsider OwnershipALPAAlpha Healthcare Acquisition Corp. III0.39%BIVIBioVie2.39%CTXRCitius Pharmaceuticals10.70%JYNTJoint27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPAAlpha Healthcare Acquisition Corp. III2,02119.31 millionN/ANot OptionableBIVIBioVie1018.57 million18.13 millionNo DataCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableJYNTJoint32015.30 million11.03 millionOptionableJYNT, ALPA, CTXR, and BIVI HeadlinesRecent News About These CompaniesWith 47% ownership, The Joint Corp. (NASDAQ:JYNT) has piqued the interest of institutional investorsJune 20 at 8:56 AM | finance.yahoo.comThe Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial OfficerJune 10, 2025 | uk.finance.yahoo.comThe Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial OfficerJune 10, 2025 | globenewswire.comMillennium Management LLC Boosts Stock Position in The Joint Corp. (NASDAQ:JYNT)June 7, 2025 | marketbeat.comJoint (NASDAQ:JYNT) to Repurchase $5.00 million in SharesJune 5, 2025 | marketbeat.comThe Joint Corp stock surges on repurchase planJune 5, 2025 | in.investing.comJoint Corp. board authorizes $5M share repurchase, commencing August 2025June 5, 2025 | msn.comJoint Corp. Appoints New Director and ChairJune 5, 2025 | tipranks.comThe Joint Corp. Announces $5 Million Stock Repurchase ProgramJune 5, 2025 | globenewswire.comThe Joint Corp. Appoints Sandi Karrmann as Director to Enhance Growth and ProfitabilityJune 4, 2025 | quiverquant.comThe Joint Corp. Appoints Sandi Karrmann as DirectorJune 4, 2025 | globenewswire.comJoint (NASDAQ:JYNT) Shares Cross Below 50-Day Moving Average - Time to Sell?May 29, 2025 | marketbeat.comC3 AI and Baker Hughes Renew and Expand Joint Venture AgreementMay 28, 2025 | businesswire.comThe Joint Corp. appoints new director for growth strategyMay 24, 2025 | uk.investing.comJYNT The Joint Corp.May 24, 2025 | seekingalpha.comPennantPark Floating Rate Capital Ltd.'s Unconsolidated Joint Venture, PennantPark Senior Secured Loan Fund I LLC Completes the Reset of its $315.8 Million Securitization, Lowering the Cost of FinancingMay 22, 2025 | globenewswire.comThe Joint Corp. Appoints Christopher M. Grandpre as New Director to Support Growth InitiativesMay 22, 2025 | quiverquant.comThe Joint Corp. Announces Christopher M. Grandpre Elected as DirectorMay 22, 2025 | globenewswire.comThe Joint Misses Q1 Earnings Estimates on Rising ExpensesMay 14, 2025 | zacks.comJoint Ventures, Strong Fundamentals, And A 4.4x P/E: Why Five Point Is A California Deep Value PlayMay 12, 2025 | seekingalpha.comThe Joint Corp. (JYNT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJYNT, ALPA, CTXR, and BIVI Company DescriptionsAlpha Healthcare Acquisition Corp. III NASDAQ:ALPAAlpha Healthcare Acquisition Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.BioVie NASDAQ:BIVI$1.03 -0.06 (-5.50%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.09 +0.06 (+5.73%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Citius Pharmaceuticals NASDAQ:CTXR$1.08 +0.17 (+18.34%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.12 +0.04 (+4.17%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Joint NASDAQ:JYNT$11.52 +0.50 (+4.54%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$11.49 -0.03 (-0.26%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
